MENU
+Compare
HBIO
Stock ticker: NASDAQ
AS OF
Apr 2 closing price
Price
$0.59
Change
-$0.00 (-0.00%)
Capitalization
184.01M

HBIO Harvard Bioscience Forecast, Technical & Fundamental Analysis

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development... Show more

Industry: #Biotechnology
HBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for HBIO with price predictions
Apr 01, 2025

HBIO's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for HBIO turned positive on March 07, 2025. Looking at past instances where HBIO's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where HBIO advanced for three days, in of 253 cases, the price rose further within the following month. The odds of a continued upward trend are .

HBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for HBIO entered a downward trend on April 01, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. HBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.530) is normal, around the industry mean (23.715). P/E Ratio (0.000) is within average values for comparable stocks, (83.458). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (1.610) is also within normal values, averaging (41.612).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

View a ticker or compare two or three
HBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

HBIO is expected to report earnings to fall 116.67% to 0 cents per share on May 13

Harvard Bioscience HBIO Stock Earnings Reports
Q1'25
Est.
$-0.01
Q4'24
Beat
by $0.01
Q3'24
Missed
by $0.04
Q2'24
Missed
by $0.05
Q1'24
Missed
by $0.03
The last earnings report on March 12 showed earnings per share of 5 cents, beating the estimate of 5 cents. With 110.96K shares outstanding, the current market capitalization sits at 184.01M.
A.I. Advisor
published General Information

General Information

a manufacturer of apparatus and scientific instruments

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Biotechnology
Address
84 October Hill Road
Phone
+1 508 893-8999
Employees
416
Web
https://www.harvardbioscience.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PWJRX29.200.14
+0.48%
PGIM Jennison International Opps R
RALYX10.540.04
+0.38%
Lazard Real Assets R6
GIEZX14.79N/A
N/A
GuideStone Funds International Eq Inv
TGDVX15.50N/A
N/A
TCW Relative Value Large Cap N
ASQCX13.01N/A
N/A
American Century Small Company C

HBIO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, HBIO has been loosely correlated with SGHT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if HBIO jumps, then SGHT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HBIO
1D Price
Change %
HBIO100%
-0.31%
SGHT - HBIO
44%
Loosely correlated
-1.75%
ICUI - HBIO
42%
Loosely correlated
+1.87%
XRAY - HBIO
42%
Loosely correlated
+1.50%
CTKB - HBIO
40%
Loosely correlated
+1.79%
NEO - HBIO
39%
Loosely correlated
+0.75%
More